Statin treatment of patients with calcific aortic valve disease modulates extracellular adenosine metabolism on the cell surface of the aortic valve

Abstract Statins efficiently prevent cardiovascular events by lipid-dependent and independent mechanisms. We hypothesize that part of these protective effects could be associated with an increased extracellular adenosine signaling. We demonstrated previously that aortic valves obtained from patients with calcific aortic valve disease (CAVD) disclosed disturbances in extracellular adenosine metabolism. This study aimed to analyze the impact of statin treatment on extracellular nucleotides and adenosine metabolism in aortic valves originated from CAVD patients and to elucidate potential mechanisms that are involved in the regulation of ecto-enzyme activities by statins. Aortic valves of CAVD patients treated with statins (n = 45) revealed higher adenosine production and its lower degradation than in non-treated patients (n = 28). Statin treatment was also related to the improvement in pre-operative echocardiographic data indicating milder aortic valve stenosis and a better function of the left ventricle. The rates of aortic valve adenosine conversions correlated with plasma lipid profile parameters, within both statin-treated and non-treated groups. Valvular extracellular AMP hydrolysis correlated negatively, while adenosine deamination positively with plasma total and LDL cholesterol. Atorvastatin treatment of murine heart endothelial cells led to the enhanced ecto-5′nucleotidase (CD73) and decreased ecto-adenosine deaminase (eADA) activity. When endothelial cells were stimulated with thrombin that induces endothelial cell exocytosis, activities of both cell-surface CD73 and eADA were increased, while co-treatment with atorvastatin reversed only thrombin-induced eADA activity. In conclusion, early intervention with statins may provide beneficial effects for CAVD therapy. Here, we presented results showing that these protective outcomes could be mediated via the regulation of extracellular adenosine metabolism pathways.

[1]  M. Yacoub,et al.  Nucleotide ecto-enzyme metabolic pattern and spatial distribution in calcific aortic valve disease; its relation to pathological changes and clinical presentation , 2019, Clinical Research in Cardiology.

[2]  J. Cullinan,et al.  Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews , 2019, BMJ Open.

[3]  Rafał Bartoszewski,et al.  Inhibition of LPS-stimulated ecto-adenosine deaminase attenuates endothelial cell activation. , 2019, Journal of molecular and cellular cardiology.

[4]  Wei Zhang,et al.  Multiple steps determine CD73 shedding from RPE: lipid raft localization, ARA1 interaction, and MMP-9 up-regulation , 2018, Purinergic Signalling.

[5]  E. Slominska,et al.  Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor‐dependent mechanisms , 2018, Journal of cellular and molecular medicine.

[6]  Seung Hyun Lee,et al.  Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy , 2018, Animal cells and systems.

[7]  S. Robson,et al.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets , 2017, Immunological reviews.

[8]  B. Sitek,et al.  Increased activity of vascular adenosine deaminase in atherosclerosis and therapeutic potential of its inhibition. , 2016, Cardiovascular research.

[9]  Narasaraju Kavalipati,et al.  Pleiotropic effects of statins , 2015, Indian journal of endocrinology and metabolism.

[10]  V. Salomaa,et al.  Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis. , 2015, Circulation research.

[11]  E. Kókai,et al.  Adenosine and inflammation: what's new on the horizon? , 2014, Drug discovery today.

[12]  M. Chopp,et al.  Statins Enhance Expression of Growth Factors and Activate the PI3K/Akt-mediated Signaling Pathway after Experimental Intracerebral Hemorrhage. , 2012, World journal of neuroscience.

[13]  J. Voorberg,et al.  Functional architecture of Weibel-Palade bodies. , 2011, Blood.

[14]  G. Scheffer,et al.  Upregulation of Ecto-5′-Nucleotidase by Rosuvastatin Increases the Vasodilator Response to Ischemia , 2010, Hypertension.

[15]  G. Müller,et al.  Transfer of the glycosylphosphatidylinositol‐anchored 5′‐nucleotidase CD73 from adiposomes into rat adipocytes stimulates lipid synthesis , 2010, British journal of pharmacology.

[16]  L. Pike.  The challenge of lipid rafts This work was supported by National Institutes of Health grants RO1 GM064491 and R01 GM082824 to LJP. Published, JLR Papers in Press, October 27, 2008. , 2009, Journal of Lipid Research.

[17]  G. Yegutkin.  Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. , 2008, Biochimica et biophysica acta.

[18]  M. Deeg,et al.  Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D. , 2007, Translational research : the journal of laboratory and clinical medicine.

[19]  Hong Yang,et al.  Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. , 2007, The Biochemical journal.

[20]  D. Isenberg,et al.  Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus1 , 2006, The Journal of Immunology.

[21]  T. Gallart,et al.  CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Yamakuchi,et al.  HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size , 2005, Circulation research.

[23]  P. Shepherd,et al.  Phosphorylation of glycosyl‐phosphatidylinositol by phosphatidylinositol 3‐kinase changes its properties as a substrate for phospholipases , 2005, FEBS letters.

[24]  P. Noris,et al.  Reversal of Thrombin-Induced Deactivation of CD39/ATPDase in Endothelial Cells by HMG-CoA Reductase Inhibition: Effects on Rho-GTPase and Adenosine Nucleotide Metabolism , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[25]  J. Michel,et al.  Lovastatin Enhances Ecto-5′-Nucleotidase Activity and Cell Surface Expression in Endothelial Cells: Implication of Rho-Family GTPases , 2002, Circulation research.

[26]  F. Ciruela,et al.  Cell surface adenosine deaminase: Much more than an ectoenzyme , 1997, Progress in Neurobiology.

[27]  W. Buurman,et al.  Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. , 1996, The American journal of physiology.

[28]  C. Garlanda,et al.  Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. D. Lima,et al.  Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review , 2017 .